logo

GRCE

Grace Therapeutics·NASDAQ
--
--(--)
--
--(--)
6.60 / 10
Outperform

Financial analysis yields good rating (6.6/10). Positive contributors: Inventory turnover ratio and Interest coverage ratio (EBIT / Interest expense) (%). Concluding evaluation: promising.

Fundamental(6.6)SentimentTechnical

Analysis Checks(10/10)

Revenue-MV
Value-0.26
Score3/3
Weight20.68%
1M Return11.03%
Total operating revenue (YoY growth rate %)
Value54.19
Score3/3
Weight1.33%
1M Return0.88%
Inventory turnover ratio
Value126.83
Score2/3
Weight-1.72%
1M Return-1.23%
Profit-MV
Value0.47
Score2/3
Weight16.60%
1M Return8.99%
PB-ROE
Value-0.43
Score3/3
Weight23.88%
1M Return13.65%
Interest coverage ratio (EBIT / Interest expense) (%)
Value48.59
Score2/3
Weight-1.79%
1M Return-1.25%
Operating revenue (YoY growth rate %)
Value74.94
Score2/3
Weight0.15%
1M Return0.10%
Asset-MV
Value-0.51
Score3/3
Weight26.34%
1M Return11.94%
Net profit / Total profit (%)
Value74.94
Score2/3
Weight-1.41%
1M Return-0.98%
Cash-MV
Value-0.07
Score2/3
Weight15.94%
1M Return8.80%
Is GRCE fundamentally strong?
  • GRCE scores 6.60/10 on fundamentals and holds a Discounted valuation at present. Backed by its -6.65% ROE, 0.00% net margin, -7.12 P/E ratio, 0.89 P/B ratio, and 41.76% earnings growth, these metrics solidify its Outperform investment rating.